Clinical effects of para-chlorophenylalanine in Parkinson's disease.
D000368:Aged; D001590:Benztropine / Q000627:therapeutic use; D001921:Brain / Q000378:metabolism*; D002986:Clinical Trials as Topic; D003863:Depression / Q000139:chemically induced; D004295:Dihydroxyphenylalanine / Q000627:therapeutic use; D005069:Evaluation Studies as Topic; D005221:Fatigue / Q000139:chemically induced; D005260:Female; D010134:Fenclonine / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D006801:Humans; D008297:Male; D001523:Mental Disorders / Q000139:chemically induced; D008875:Middle Aged; D009325:Nausea / Q000139:chemically induced; D010300:Parkinson Disease / Q000188:drug therapy* / Q000378:metabolism; D010919:Placebos; D012701:Serotonin / Q000378:metabolism*; D007319:Sleep Initiation and Maintenance Disorders / Q000139:chemically induced
D010919:Placebos; D001590:Benztropine; D012701:Serotonin; D004295:Dihydroxyphenylalanine; D010134:Fenclonine